| Jnana Therapeutics Emerges with $50M to Find Cellular Protein Drugs | Frank Vinluan | 12/15/17 | Boston |
| Bio Roundup: NIH Precision Boost, AHCA to Senate, New Drugs & More | Ben Fidler | 05/05/17 | National |
| Bio Roundup: New Drug Bonanza, Vertex’s Triple Play, CAR-T Race & More | Ben Fidler | 03/31/17 | National |
| Tocagen Plans IPO to Finance Trials of Gene Therapy in Brain Cancer | Frank Vinluan | 03/10/17 | San Diego |
| Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More | Ben Fidler | 01/13/17 | National |
| Takeda, Maverick Therapeutics Enter $125M Cancer Therapy Partnership | Frank Vinluan | 01/11/17 | San Francisco |
| Bio Roundup: Jenkins Gets Mad, Bernie Gets His Pen, CRISPR IPO & J-Lo | Alex Lash | 10/21/16 | National |
| East Coast Biotech Roundup: NY Bio, Gender Gap, Zafgen, PureTech & More | Ben Fidler | 05/12/16 | Boston |
| Ariad Sells Off Europe Hub, Drug Rights in $140M Incyte Deal | Ben Fidler | 05/09/16 | Boston |
| East Coast Biotech Roundup: NY Disruptors, Commense, Regeneron, & More | Ben Fidler | 04/01/16 | Boston |
| East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More | Ben Fidler | 09/04/15 | Boston |
| East Coast Biotech Roundup: Regeneron, Synergy, Foundation & More | Ben Fidler | 07/31/15 | Boston |
| Ariad Searches For New Leader As Berger Steps Down, Ending Proxy Battle | Ben Fidler | 04/29/15 | Boston |
| East Coast Biotech Roundup: Cellectis, Bristol, What’s Hot & More | Ben Fidler | 04/13/15 | Boston |
| East Coast Biotech Roundup: Vertex, Syndax, Build-to-Buy Deals & More | Ben Fidler | 02/20/15 | Boston |
| East Coast Biotech Roundup: Genzyme, 21st Century Cures, Acorda, & More | Ben Fidler | 02/13/15 | Boston |
| 10 Takeaways From New York’s Life Science Disruptors | Ben Fidler | 03/10/14 | New York |
| East Coast Biotech Roundup: Sigal, Radius, SHIN-NY, & More | Ben Fidler | 02/28/14 | Boston |
| East Coast Biotech Roundup: Scholar Rock, Dicerna, Eleven, & More | Ben Fidler | 01/03/14 | Boston |
| Xconomy Boston’s Top 10 Stories of Q4: Editor’s Picks | Gregory T. Huang | 12/30/13 | Boston |
| Ariad’s Cancer Drug to Return to U.S. in January, Shares Soar | Ben Fidler | 12/20/13 | Boston |
| East Coast Biotech Roundup: Arno, Accelerate LI, Immunogen, & More | Ben Fidler | 11/08/13 | Boston |
| Axe Falls on Ariad’s Workforce After Cancer Drug Blowup | Ben Fidler | 11/07/13 | Boston |
| East Coast Biotech Roundup: Vertex, Dimension, Merrimack, & More | Ben Fidler | 11/01/13 | Boston |
| Ariad Pulls Cancer Drug Off the Market as Trial Fallout Continues | Ben Fidler | 10/31/13 | Boston |
| East Coast Life Sciences Roundup: Verdine, Ariad, Karyopharm, & More | Ben Fidler | 10/11/13 | Boston |
| Ariad Halts Leukemia Drug Trials Due to Safety Concerns, Shares Plummet | Ben Fidler | 10/09/13 | Boston |
| Bellicum in Trials with Cancer Vaccine, Cell-Suicide Switches | Iris Kuo | 05/16/13 | Texas |
| Poll: Which of These 10 New Drugs Is Priced Too High? | Luke Timmerman | 02/11/13 | National |
| Companion Diagnostics for Cancer Drugs Advancing Personalized Medicine | Catherine Arnst | 01/31/13 | Boston |
